This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Griseofulvin

Authoring team

Griseofulvin is only approved as a systemic (oral) agent and is indicated for the treatment of dermatophytoses of the skin, hair, and nails, which is severe or refractory to topical therapy. Specifically, this drug treats tinea (corporis, pedis, cruris, barbae, capitis, and unguium) where topical therapy has failed or is inappropriate

Cautions:

  • Rarely aggravation or precipitation of SLE

Contra-indications:

  • Porphyria
  • Pregnancy
  • Liver failure

Side-effects:

  • Rashes
  • Headache
  • Nausea and vomiting
  • Photosensitivity

Routes of administration:

  • Oral
    • Tablets
    • Suspension

Check with summary of product characteristics before prescribing this drug.

References:

  1. McKeny T et al. Antifungal Antibiotics. Treasure Island (FL): StatPearls Publishing. 2025 Jan.
  2. British National Formulary (BNF); NICE Evidence Services (UK access only).

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.